Natco Pharma Pomalidomide capsules get USFDA okay
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced that the company's marketing partner, Breckenridge Pharmaceutical Inc., has received final approval for its Abbreviated New Drug Application (ANDA) for Pomalidomide Capsules, from the U.S. Food and Drug Administration (USFDA).
In addition, NATCO and Breckenridge have settled the patent litigation with Celgene (now part of Bristol-Myers Squibb) in the U.S. district court for this product.
Celgene, sells Pomalidomide Capsules under Brand name POMALYST, in the USA market which is indicated for the treatment of patients suffering from multiple myeloma cancer.
As per industry sales data, POMALYST had annual sales of $957 million during the twelve months ending September 2020.
Read also: Natco Pharma to launch 10 new products in India in near term
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
